Pharmaceuticals

Rare Disease Genome Editing Market Outlook 2026–2030 Driven By Growth Factors And Projections

May 4, 2026May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Rare Disease Genome Editing Market In 2026, And How Will Its Value Evolve By 2030?

The rare disease genome editing market size has experienced rapid growth in recent years. It is projected to expand from $1.29 billion in 2025 to $1.51 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.8%. This growth during the historical period is attributable to advancements in gene editing technologies, a rise in the identification of rare genetic mutations, increased funding for genomic research, early positive results from gene therapy trials, and expanding academic research initiatives.

The rare disease genome editing market size is projected to experience substantial growth over the next few years. It is forecast to expand to $2.88 billion by 2030, achieving a compound annual growth rate (CAGR) of 17.5%. This growth during the forecast period is fueled by escalating investment in curative rare disease therapies, the increasing embrace of precision medicine strategies, the expansion of clinical genome editing trials, growing regulatory support for orphan drugs, and increased collaboration between biotechnology companies and healthcare providers. Prominent trends for the upcoming period encompass the wider adoption of CRISPR-based therapeutics, a heightened focus on gene editing for monogenic disorders, the expanding utilization of personalized genome editing approaches, the development of advanced editing platforms, and enhanced integration of genomic data analytics.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28313&type=smp

What Significant Factors Are Influencing The Rare Disease Genome Editing Market Expansion?

An escalating emphasis on precision medicine is anticipated to drive expansion within the rare disease genome editing market moving ahead. This tailored healthcare strategy, known as precision medicine, leverages an individual’s genetics, environmental factors, and lifestyle choices to deliver more precise and impactful treatments. The rising prominence of precision medicine stems from progress in genomic sequencing and the identification of biomarkers, which facilitate accurate diagnosis and specialized treatments. The rare disease genome editing market supports precision medicine through its capacity to allow for the focused correction of genetic mutations, leading to more customized and efficacious therapies. This contributes to healthcare progress by tackling the fundamental origins of rare conditions, enhancing patient results, and lessening dependence on managing symptoms alone. For example, in March 2024, Novotech, a biotechnology firm based in Australia, reported that in 2023, 43% of the 217 FDA-approved oncology therapies qualified as precision oncology treatments, with 78 of these involving DNA or NGS-detectable biomarkers. Consequently, the growing attention on precision medicine is propelling the expansion of the rare disease genome editing market.

What Are The Main Segments Within The Rare Disease Genome Editing Market Segment Structure?

The rare disease genome editing market covered in this report is segmented –

1) By Technology: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9, Transcription Activator-Like Effector Nucleases (TALEN), Zinc Finger Nucleases (ZFN), Other Technologies

2) By Disease Type: Monogenic Disorders, Multifactorial Disorders, Chromosomal Disorders

3) By Application: Therapeutics, Research

4) By End User: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Hospitals

Subsegments:

1) By Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or CRISPR-Associated Protein 9: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 9, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 12, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Protein 13, Base Editing, Prime Editing

2) By Transcription Activator-Like Effector Nucleases (TALEN): Standard Transcription Activator-Like Effector Nucleases (TALEN), Designer Transcription Activator-Like Effector Nucleases (dTALEN), Transcription Activator-Like Effector Nucleases (TALEN) Paired Nucleases

3) By Zinc Finger Nucleases (ZFN): Standard Zinc Finger Nucleases (ZFN), Engineered Zinc Finger Nucleases (ZFN), Modular Zinc Finger Nucleases (ZFN)

4) By Other Technologies: Meganucleases, Ribonucleic Acid (RNA)-Guided Nucleases, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Associated Transposases

What Trends Are Affecting The Direction Of The Rare Disease Genome Editing Market?

Leading companies within the rare disease genome editing market are concentrating on the creation of sophisticated therapeutic platforms, such as CRISPR-based gene editing systems, aiming to boost treatment accuracy, elevate patient outcomes, and tackle genetic conditions previously lacking cures. These innovative CRISPR-based gene editing systems represent technologies capable of precise genomic alterations, enabling the rectification of genetic flaws or the insertion of therapeutic genes into cells. A notable example occurred in December 2023, when US-based biopharmaceutical company Vertex Pharmaceuticals Inc., collaborating with US-based biotechnology research company CRISPR Therapeutics Inc., secured conditional marketing approval from the United Kingdom (U.K.) Medicines and Healthcare products Regulatory Agency (MHRA) for their product, CASGEVY (exagamglogene autotemcel, exa-cel). This therapy is prescribed for individuals aged 12 and above who suffer from sickle cell disease (SCD) with recurring vaso-occlusive crises or transfusion-dependent beta thalassemia (TDT). Casgevy functions by modifying a patient’s hematopoietic stem cells, thereby reactivating fetal hemoglobin production, which subsequently diminishes or eradicates disease symptoms and presents a potential functional cure for these ailments.

Who Are The Companies Participating In The Rare Disease Genome Editing Market?

Major companies operating in the rare disease genome editing market are Regeneron Pharmaceuticals Inc., Sarepta Therapeutics Inc., Ultragenyx Pharmaceutical Inc., Beam Therapeutics Inc., CRISPR Therapeutics AG, Rocket Pharmaceuticals Inc., Sangamo Therapeutics Inc., Arcturus Therapeutics Holdings Inc., Editas Medicine Inc., Krystal Biotech Inc., Caribou Biosciences Inc, Bluebird Bio Inc., SpliceBio S.L., Cellectis SA, Generation Bio Co., iECURE Inc., Affinia Therapeutics Inc., Precision Biosciences Inc., Intellia Therapeutics Inc., MeiraGTx Holdings plc

Get The Full Rare Disease Genome Editing Market Report:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

Which Region Has The Greatest Market Share In The Rare Disease Genome Editing Market?

North America was the largest region in the rare disease genome editing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare disease genome editing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Rare Disease Genome Editing Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/rare-disease-genome-editing-global-market-report

Browse Through More Reports Similar to the Global Rare Disease Genome Editing Market 2026, By The Business Research Company

Genome Editing Or Genome Engineering Market Report 2026

https://www.thebusinessresearchcompany.com/report/genome-editing-or-genome-engineering-global-market-report

Crispr Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/crispr-gene-editing-global-market-report

Gene Editing Market Report 2026

https://www.thebusinessresearchcompany.com/report/gene-editing-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795